A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1355-1362

  Planque, Chris ^a,b   Li, Lin ^c   Zheng, Yingye ^c   Soosaipillai, Antoninus ^a,b   Reckamp, Karen ^d   Chia, David ^e   Diamandis, Eleftherios P ^a,b   Goodglick, Lee ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 10; KALLIKREIN 11; KALLIKREIN 12; KALLIKREIN 13; KALLIKREIN 14; KALLIKREIN 4; KALLIKREIN 5; KALLIKREIN 7; NEUROPSIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; SMOKING; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 40949162278     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4117     Document Type: Article

References (44)

1. Brambilla E. [Classification of broncho-pulmonary cancers (WHO 1999)]. Rev Mal Respir 2002;19:455-66.
2. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
3. Duffy MJ. Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 1987;23:583-9.
4. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
5. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5. Epub 2001 Nov 13.
6. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
7. Planque C, de Monte M, Guyetant S, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun 2005;329:1260 - 6.
8. Planque C, Ainciburu M, Heuze-Vourc'h N, Regina S, de Monte M, Courty Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem 2006;387:783-8.
9. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem 2006;387:653-63.
10. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423-32.
11. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002;58:657-64.
12. Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996;40:171-8.
13. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996;56:3371-9.
14. Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family - differential expression in breast cancer [in process citation]. Genomics 2000;69:331-41.
15. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis 2003;6:223-7.
16. Yousef GM, Scorilas A, Chang A, et al. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002;51:126-32.
17. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002;60:714-8.
18. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001;85:220-4.
19. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
20. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-41.
21. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
22. Borgono CA, Michael IP, Shaw JL, et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007;282:2405-22.
23. Sasaki H, Kawano O, Endo K, et al. Decreased kallikrein 11 messenger RNA expression in lung cancer. Clin Lung Cancer 2006;8:45-8.
24. Mitsui S, Yamada T, Okui A, Kominami K, Uemura H, Yamaguchi N. A novel isoform of a kallikrein-like protease, TLSP/hippostasin (PRSS20), is expressed in the human brain and prostate. Biochem Biophys Res Commun 2000;272:205-11.
25. Kurlender L, Borgono C, Michael IP, et al. A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 2005;1755:1-14.
26. Tan OL, Whitbread AK, Clements JA, Dong Y. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol Chem 2006;387:697-705.
27. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
28. Yousef GM, Kapadia C, Polymeris ME, et al. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim Biophys Acta 2003;1628:88-96.
29. Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, Diamandis EP. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin Chim Acta 2004;339:157-67.
30. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998;34:44-50.
31. Obiezu CV, Shan SJ, Soosaipillai A, et al. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 2005;51:1432-42.
32. Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996;155:1099-103.
33. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001;7:2363-71.
34. Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001;7:2380-6.
35. Davidson B, Xi Z, Klokk TI, et al. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. Am J Clin Pathol 2005;123:360-8.
36. Shih Ie M, Salani R, Fiegl M, et al. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 2007;105:501-7.
37. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta 2007;381:78-84.
38. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79.
39. Sher YP, Chou CC, Chou RH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res 2006;66:11763-70.
40. Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol 2007;30:1493-8.
41. Stenman UH. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 1999;45:753-4.
42. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;63:6543-6.
43. Stephan C, Meyer HA, Cammann H, Nakamura T, Diamandis EP, Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 2006;387:801-5.
44. Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-18.